Jenkem Technology Announcement: Jin Kei Technology Co., Ltd., a wholly-owned subsidiary, independently developed polyethylene glycol irbesartan for injection (drug code: JK1201I) for the treatment of small cell lung cancer, has recently completed the first subject enrollment in the Phase III clinical trial. This drug is a small molecule long-acting anti-cancer innovative drug in Class 1 developed independently by the company, which showed better efficacy and safety than the commercially available irbesartan hydrochloride in the previous non-clinical trials. The company will actively promote the above-mentioned research and development project and fulfill the obligation of timely information disclosure on the subsequent progress of the project.